The Knowledge Group Has Scheduled a Live Webcast on The Hatch-Waxman Act: Recent Amendments and Developments
New York, NY, November 25, 2017 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, announced today that it has scheduled a live webcast entitled: The Hatch-Waxman Act: Recent Amendments and Developments LIVE Webcast. This event is scheduled on December 14, 2017 from 12:00 pm to 1:30 pm (ET).
Event Synopsis:
The Hatch-Waxman Act is one of the most important regulators of competition between brand and generic pharmaceutical companies. Because of its provisions, the pharma industry has continuously achieved balance when it comes to patent protection and entry of a new drug. By requiring the abbreviated new drug application (ANDA) process, Hatch-Waxman regulates the approval of a "bioequivalent" generic drug while protecting the patent rights of an existing brand drug.
Because of its significant impact on both brand and generic drug companies, it is imperative for the pharma industry to keep abreast of the latest developments in Hatch-Waxman Act: amendments, as well as potential changes in the year ahead.
Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of the Hatch-Waxman Act. Listen as they delve into an in-depth analysis of the latest developments and trends involving FDA applications — approvals and rejections. Speakers will also provide the audience with practical strategies when it comes to ANDA litigation.
This Live webcast will discuss the following key topics:
§ The Hatch-Waxman Act: Overview and Legal Framework
§ Latest Developments
§ The Abbreviated New Drug Application (ANDA) Process
§ Latest Developments in ANDA Litigation
§ Recent FDA Applications
§ The Hatch-Waxman Act in 2018 – An Outlook
Speakers/Faculty Panel:
Mark T. Deming
Shareholder
Polsinelli
Martin B. Pavane
Vice Chair, Intellectual Property Department, Co-Chair, Hatch-Waxman & Biologics Litigation
Cozen O'Connor
Joseph Reisman
Partner
Knobbe Martens Olson & Bear LLP
For an updated list of the faculty panel, please visit: https://www.theknowledgegroup.org/webcasts/healthcare/health-law-healthcare/the-hatch-waxman-act
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group brings together the world's leading authorities and industry participants through informative two-hour webcasts that study the impact of changing regulations and help businesses succeed through proper regulatory compliance.
Visit http://theknowledgegroup.org/ for further information and inquiry.
Event Synopsis:
The Hatch-Waxman Act is one of the most important regulators of competition between brand and generic pharmaceutical companies. Because of its provisions, the pharma industry has continuously achieved balance when it comes to patent protection and entry of a new drug. By requiring the abbreviated new drug application (ANDA) process, Hatch-Waxman regulates the approval of a "bioequivalent" generic drug while protecting the patent rights of an existing brand drug.
Because of its significant impact on both brand and generic drug companies, it is imperative for the pharma industry to keep abreast of the latest developments in Hatch-Waxman Act: amendments, as well as potential changes in the year ahead.
Join a panel of key thought leaders and practitioners assembled by The Knowledge Group as they bring the audience to a road beyond the basics of the Hatch-Waxman Act. Listen as they delve into an in-depth analysis of the latest developments and trends involving FDA applications — approvals and rejections. Speakers will also provide the audience with practical strategies when it comes to ANDA litigation.
This Live webcast will discuss the following key topics:
§ The Hatch-Waxman Act: Overview and Legal Framework
§ Latest Developments
§ The Abbreviated New Drug Application (ANDA) Process
§ Latest Developments in ANDA Litigation
§ Recent FDA Applications
§ The Hatch-Waxman Act in 2018 – An Outlook
Speakers/Faculty Panel:
Mark T. Deming
Shareholder
Polsinelli
Martin B. Pavane
Vice Chair, Intellectual Property Department, Co-Chair, Hatch-Waxman & Biologics Litigation
Cozen O'Connor
Joseph Reisman
Partner
Knobbe Martens Olson & Bear LLP
For an updated list of the faculty panel, please visit: https://www.theknowledgegroup.org/webcasts/healthcare/health-law-healthcare/the-hatch-waxman-act
About The Knowledge Group/The Knowledge Congress Live Webcast Series
The Knowledge Group brings together the world's leading authorities and industry participants through informative two-hour webcasts that study the impact of changing regulations and help businesses succeed through proper regulatory compliance.
Visit http://theknowledgegroup.org/ for further information and inquiry.
Contact
The Knowledge Group
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Contact
Thomas LaPointe, Jr., Executive Director
646-844-0200
www.theknowledgegroup.org
Therese Lumbao, Director
Account Management & Member Services
tlumbao@knowledgecongress.org
Categories